DePuy ASR Recall: 12,000 Patients Will Need Revision Surgery

The DePuy ASR recall affects over 90,000 hip implant patients - of which approximately 12,000 will have to undergo additional hip replacement surgeries.

2010-11-03

SAUSALITO, CA, November 03, 2010 (Press-News.org) The August 2010 DePuy ASR recall affects over 90,000 hip implant patients - of which approximately 12,000 will likely have to undergo additional, painful and expensive hip replacement surgeries - not to mention medical monitoring for heavy metal toxicity issues due to metal debris entering the blood stream.

DePuy ASR Hip Recall Announced After 13% Failure Rate Released

The August 2010 DePuy ASR recall of the ASR XL Acetabular System and the ASR Hip Resurfacing System will affect over 90,000 hip implant patients around the world. DePuy only recalled these metal-on-metal devices after the U.S. Food & Drug Administration (FDA) received hundreds of complaints from consumers alleging that the devices were defective.

After further investigation, it was revealed that nearly 13% of those patients - about 12,000 people - would likely have to undergo additional hip replacement surgeries to replace the very same hip implant they assumed would last for years and years. While that's bad enough, issues of heavy metal toxicity in all 90,000+ DePuy hip implant patients could result in serious injuries for many down the road.

Metal-On-Metal Debris May Cause Heavy Metal Toxicity

DePuy hip implant lawyers say that all patients who were implanted with a DePuy ASR hip replacement system since 2003 may be susceptible to heavy metal toxicity due to chromium and cobalt parts rubbing together and creating metal debris, or metal ions, that can enter a patient's blood stream and cause serious injuries. Doctors say that even if an injury hasn't yet manifested, patients should be continually and consistently monitored in the future - and that DePuy Orthopedics, a Johnson & Johnson Company, should pay for that.

Contact a DePuy hip recall lawyer to find out how to receive the compensation you deserve for the manufacturers' failure to warn you about its products defects and for waiting too long to recall those products.

Online since 1999, FreeAdvice.com provides consumers and small businesses with balanced and comprehensive legal information covering over 125 legal topics. These useful and professionally prepared answers to thousands of legal questions are written, reviewed, and updated by lawyers from leading law firms across the country. For further information, please contact us at 240-462-5858.
Website: http://www.freeadvice.com

ELSE PRESS RELEASES FROM THIS DATE:

Appearances Can Be Deceiving in Sleep Apnea Cases: Even Athletes are at Risk

2010-11-03

A recent article on the Men's Health website told a cautionary tale of a man named Tom Zehmisch. He died suddenly of a heart attack at the age of 46. Only four months earlier, he had participated in a national swim meet and he died while participating in a triathlon. To look at Tom, you would not have thought him to be at risk of obstructive sleep apnea. The stereotypical obstructive sleep apnea patient is more like Don Dillard who, in 2007 had reached a staggering 401 pounds on the scale. He had been hospitalized four times for serious health problems including congestive ...

Madison Who's Who Bulletin Board is Now Available!

2010-11-03

Madison Who's Who has officially launched the bulletin board feature on their website, www.madisonwhoswho.com. This impressive new feature is another added benefit to the members of Madison Who's Who business networking directory. The Madison Who's Who bulletin board feature is secure and easy to use with password entry and available exclusively to Madison Who's Who members only. It offers a powerful search facility along with multiple forums and categories. Madison Who's Who offers the best in business networking; this new feature is an extension of the Madison Who's ...

Possible new drug targets for the genetic disorder Noonan syndrome

2010-11-02

Noonan syndrome is a relatively common genetic disorder characterized by short stature, unique facial features, and heart defects. About 10%-15% of affected individuals have mutations in their SOS1 gene. A team of researchers, led by Raju Kucherlapati, at Harvard Medical School, Boston, has now generated mice expressing a Sos1 mutation associated with Noonan syndrome and used them to identify potential therapeutic targets for the treatment of individuals with Noonan syndrome. Specifically, the team found that the Ras/MAPK signaling pathway as well as the Rac and Stat3 proteins ...

JCI online early table of contents: Nov. 1, 2010

2010-11-02

EDITOR'S PICK: New potential drug combination for most common form of non-Hodgkin lymphoma Diffuse large B cell lymphoma (DLBCL) is the most common form of non-Hodgkin lymphoma. Although 60% of patients can be cured with a currently available combination therapy, this leaves a substantial number of patients without a cure. However, a team of researchers, led by Ari Melnick, at Weill Cornell Medical College, New York, has now identified a potential new combinatorial therapy for DLBCL. Specifically, the team found that combining an inhibitor of the protein BCL6 with either ...

Expanding croplands chipping away at world's carbon stocks

2010-11-02

Editor's note: Images to accompany this story are available at http://www.news.wisc.edu/newsphotos/carbon-cycle.html END ...

What happens after traumatic brain injury occurs?

2010-11-02

Reston, Va.— Results from a study published in the November issue of The Journal of Nuclear Medicine (JNM) show that powerful imaging techniques––positron emission tomography (PET) fused with magnetic resonance imaging (MRI)––are helping researchers better understand the long-term functional and structural changes that take place after traumatic brain injury (TBI). "The results provide new insights into the progressive nature of the brain changes occurring following TBI, demonstrating that changes in brain structure and function after TBI are dynamic and continue to progress ...

AAN: Any athlete suspected of having concussion should be removed from play

2010-11-02

ST. PAUL, Minn. – The American Academy of Neurology (AAN) is calling for any athlete who is suspected of having a concussion to be removed from play until the athlete is evaluated by a physician with training in the evaluation and management of sports concussion. The request is one of five recommendations from a new position statement approved by the AAN's Board of Directors that targets policymakers with authority over determining the policy procedures for when an athlete suffers from concussion while participating in a sporting activity. "While the majority of ...

Utah researchers discover how brain is wired for attention

2010-11-02

SALT LAKE CITY—University of Utah (U of U) medical researchers have uncovered a wiring diagram that shows how the brain pays attention to visual, cognitive, sensory, and motor cues. The research provides a critical foundation for the study of abnormalities in attention that can be seen in many brain disorders such as autism, schizophrenia, and attention deficit disorder. The study appears Nov. 1, 2010, online in the Proceedings of the National Academy of Sciences (PNAS). "This study is the first of its kind to show how the brain switches attention from one feature to ...

Time for a rain dance?

2010-11-02

In many areas of the world, including California's Mojave Desert, rain is a precious and rare resource. To encourage rainfall, scientists use "cloud seeding," a weather modification process designed to increase precipitation amounts by dispersing chemicals into the clouds. But research now reveals that the common practice of cloud seeding with materials such as silver iodide and frozen carbon dioxide may not be as effective as it had been hoped. In the most comprehensive reassessment of the effects of cloud seeding over the past fifty years, new findings from Prof. Pinhas ...

New drug may provide more cost-effective stroke prevention than warfarin, Stanford/VA study shows

2010-11-02

STANFORD, Calif. — A newly approved drug may be a cost-effective way to prevent stroke in patients with an irregular heart rhythm — and may also offer patients better health outcomes than the commonly prescribed, but potentially risky, blood thinner warfarin. That's according to a new analysis from researchers at the Stanford University School of Medicine and the Veterans Affairs Palo Alto Health Care System. "Dabigatran is the first new drug in 20 years to be approved for stroke prevention in atrial fibrillation, and we wanted to see if it could be cost-effective even ...